Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains

Executive Summary

Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).


Related Content

Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus
Pfizer/Lilly ready to ditch painful past with new tanezumab trials
US FDA panel: Let anti-NGF studies move forward, despite 'severe' joint risks
J&J, Regeneron follow Pfizer in clinical holds for anti-NGFs
Pfizer forced to discontinue more trials for novel pain drug tanezumab
Pfizer suspends worldwide studies for tanezumab in osteoarthritis


Related Companies